Literature DB >> 7879653

TCA-100 tumour chemosensitivity assay: differences in sensitivity between cultured tumour cell lines and clinical studies.

P E Andreotti1, D Linder, D M Hartmann, I A Cree, M Pazzagli, H W Bruckner.   

Abstract

The BATLE LE TCA-100 tumour chemosensitivity assay has been used to evaluate chemotherapeutic drug sensitivity of cultured tumour cell lines. Studies were performed using test drug concentrations calibrated to discriminate sensitivity and resistance of clinical specimens. Strong sensitivity which appeared to be inconsistent with clinical experience was detected for some drugs and cell lines. Findings of strong sensitivity were consistent with basic differences between sensitivity testing cultured cell lines and clinical specimens. Results with cell lines frequently may not apply directly to clinical applications. Characterization of differences between cell lines and clinical specimens may assist in application of cell line findings to clinical trials.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7879653     DOI: 10.1002/bio.1170090604

Source DB:  PubMed          Journal:  J Biolumin Chemilumin        ISSN: 0884-3996


  7 in total

1.  Uveal melanomas express vascular endothelial growth factor and basic fibroblast growth factor and support endothelial cell growth.

Authors:  S R Boyd; D S W Tan; L de Souza; M H Neale; N E Myatt; R A Alexander; M Robb; J L Hungerford; I A Cree
Journal:  Br J Ophthalmol       Date:  2002-04       Impact factor: 4.638

2.  Heterogeneity of in vitro chemosensitivity in perioperative breast cancer cells to mitoxantrone versus doxorubicin evaluated by a microplate ATP bioluminescence assay.

Authors:  C M Kurbacher; I A Cree; U Brenne; H W Bruckner; J A Kurbacher; P Mallmann; P E Andreotti; D Krebs
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

3.  The effect of pentamidine on melanoma ex vivo.

Authors:  Jason Smith; Benjamin J Stewart; Sharon Glaysher; Katharine Peregrin; Louise A Knight; David J Weber; Ian A Cree
Journal:  Anticancer Drugs       Date:  2010-02       Impact factor: 2.248

4.  Evaluation of novel histone deacetylase inhibitors as therapeutic agents for colorectal adenocarcinomas compared to established regimens with the histoculture drug response assay.

Authors:  Jin C Kim; Dae D Kim; Yoo M Lee; Tae W Kim; Dong H Cho; Moon B Kim; Seong G Ro; Seon Y Kim; Yong S Kim; Jung S Lee
Journal:  Int J Colorectal Dis       Date:  2008-10-01       Impact factor: 2.571

5.  Cancer cell adaptation to chemotherapy.

Authors:  Federica Di Nicolantonio; Stuart J Mercer; Louise A Knight; Francis G Gabriel; Pauline A Whitehouse; Sanjay Sharma; Augusta Fernando; Sharon Glaysher; Silvana Di Palma; Penny Johnson; Shaw S Somers; Simon Toh; Bernie Higgins; Alan Lamont; Tim Gulliford; Jeremy Hurren; Constantinos Yiangou; Ian A Cree
Journal:  BMC Cancer       Date:  2005-07-18       Impact factor: 4.430

Review 6.  Molecular chess? Hallmarks of anti-cancer drug resistance.

Authors:  Ian A Cree; Peter Charlton
Journal:  BMC Cancer       Date:  2017-01-05       Impact factor: 4.430

7.  Effect of Chemotherapeutic Drugs on Caspase-3 Activity, as a Key Biomarker for Apoptosis in Ovarian Tumor Cell Cultured as Monolayer. A Pilot Study.

Authors:  Ewa L Gregoraszczuk; Agnieszka Rak-Mardyła; Janusz Ryś; Jerzy Jakubowicz; Krzysztof Urbański
Journal:  Iran J Pharm Res       Date:  2015       Impact factor: 1.696

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.